JPS6140231B2 - - Google Patents
Info
- Publication number
- JPS6140231B2 JPS6140231B2 JP13527680A JP13527680A JPS6140231B2 JP S6140231 B2 JPS6140231 B2 JP S6140231B2 JP 13527680 A JP13527680 A JP 13527680A JP 13527680 A JP13527680 A JP 13527680A JP S6140231 B2 JPS6140231 B2 JP S6140231B2
- Authority
- JP
- Japan
- Prior art keywords
- lactone
- hexane
- radioactivity
- fraction
- isopropanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 26
- GMRQFYUYWCNGIN-NKMMMXOESA-N calcitriol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-NKMMMXOESA-N 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 9
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 229930003316 Vitamin D Natural products 0.000 description 4
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 210000003734 kidney Anatomy 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000011710 vitamin D Substances 0.000 description 4
- 235000019166 vitamin D Nutrition 0.000 description 4
- 150000003710 vitamin D derivatives Chemical class 0.000 description 4
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical class C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 4
- 229940046008 vitamin d Drugs 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 102000003982 Parathyroid hormone Human genes 0.000 description 3
- 108090000445 Parathyroid hormone Proteins 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000005805 hydroxylation reaction Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 150000002596 lactones Chemical group 0.000 description 3
- XELZGAJCZANUQH-UHFFFAOYSA-N methyl 1-acetylthieno[3,2-c]pyrazole-5-carboxylate Chemical compound CC(=O)N1N=CC2=C1C=C(C(=O)OC)S2 XELZGAJCZANUQH-UHFFFAOYSA-N 0.000 description 3
- 239000000199 parathyroid hormone Substances 0.000 description 3
- 229960001319 parathyroid hormone Drugs 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- WMYIVSWWSRCZFA-RWVJFQLJSA-N 1,25-Dihydroxyvitamin D3-26,23-lactone Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)[C@H]1C[C@@](C)(O)C(=O)O1 WMYIVSWWSRCZFA-RWVJFQLJSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000011612 calcitriol Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 150000003704 vitamin D3 derivatives Chemical class 0.000 description 2
- JWUBBDSIWDLEOM-XHQRYOPUSA-N (3e)-3-[(2e)-2-[1-(6-hydroxy-6-methylheptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol Chemical compound C1CCC2(C)C(C(CCCC(C)(C)O)C)CCC2\C1=C\C=C1/CC(O)CCC1=C JWUBBDSIWDLEOM-XHQRYOPUSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 201000002980 Hyperparathyroidism Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- OFHCOWSQAMBJIW-AVJTYSNKSA-N alfacalcidol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C OFHCOWSQAMBJIW-AVJTYSNKSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000000457 gamma-lactone group Chemical group 0.000 description 1
- QKGYJVXSKCDGOK-UHFFFAOYSA-N hexane;propan-2-ol Chemical compound CC(C)O.CCCCCC QKGYJVXSKCDGOK-UHFFFAOYSA-N 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- -1 polyethylene Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- BJYLYJCXYAMOFT-RSFVBTMBSA-N tacalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CC[C@@H](O)C(C)C)=C\C=C1\C[C@@H](O)C[C@H](O)C1=C BJYLYJCXYAMOFT-RSFVBTMBSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Furan Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13527680A JPS5759881A (en) | 1980-09-30 | 1980-09-30 | 1alpha,25-dihydroxyvitamin d3-26,23-lactone |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP13527680A JPS5759881A (en) | 1980-09-30 | 1980-09-30 | 1alpha,25-dihydroxyvitamin d3-26,23-lactone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5759881A JPS5759881A (en) | 1982-04-10 |
| JPS6140231B2 true JPS6140231B2 (enrdf_load_stackoverflow) | 1986-09-08 |
Family
ID=15147916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13527680A Granted JPS5759881A (en) | 1980-09-30 | 1980-09-30 | 1alpha,25-dihydroxyvitamin d3-26,23-lactone |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5759881A (enrdf_load_stackoverflow) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0531861A (ja) * | 1991-07-26 | 1993-02-09 | Sumitomo Bakelite Co Ltd | 密封容器 |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4632784A (en) * | 1983-01-28 | 1986-12-30 | Hoffmann-La Roche Inc. | Process for the preparation of 1α,23,25-trihydroxycholecalciferol-26-oic acid 23,26-lactone |
| JPS59148775A (ja) * | 1983-02-14 | 1984-08-25 | Teijin Ltd | ２５―ヒドロキシビタミンｄ３―２６，２３―ラクトン誘導体 |
-
1980
- 1980-09-30 JP JP13527680A patent/JPS5759881A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0531861A (ja) * | 1991-07-26 | 1993-02-09 | Sumitomo Bakelite Co Ltd | 密封容器 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5759881A (en) | 1982-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Reddy et al. | Calcitroic acid, end product of renal metabolism of 1, 25-dihydroxyvitamin D3 through the C-24 oxidation pathway | |
| US3697559A (en) | 1,25-dihydroxycholecalciferol | |
| KR950005776B1 (ko) | 신규 1α-히드록시비타민D_2에피머 및 유도체 | |
| JP2002516307A (ja) | １α−ヒドロキシ−２５−エン−ビタミンＤ、類似体及びその使用 | |
| Slatopolsky et al. | Effects of 19-nor-1, 25 (OH) 2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats | |
| Napoli et al. | Intestinal synthesis of 24-keto-1, 25-dihydroxyvitamin D3. A metabolite formed in vivo with high affinity for the vitamin D cytosolic receptor. | |
| Jones et al. | A dialogue on analogues newer vitamin-D drugs for use in bone disease, psoriasis, and cancer | |
| JPH0348903B2 (enrdf_load_stackoverflow) | ||
| CA2013166C (en) | Suppression of parathyroid hormone synthesis and secretion | |
| JPH0610188B2 (ja) | １α，２５―ジヒドロキシル化ビタミンＤ▼下２▲化合物の前駆体 | |
| Onisko et al. | Metabolites of 1. alpha., 25-dihydroxyvitamin D3 in rat bile | |
| FR2558829A1 (fr) | Isomeres de l'hydroxyvitamine d2, composition pharmaceutique et procede de preparation | |
| Goldenberg | Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis | |
| JPS6140231B2 (enrdf_load_stackoverflow) | ||
| KR940003360B1 (ko) | 불포화 측쇄를 갖는 1α-히드록시비타민 D동족체 | |
| Haussler | Characterization of the metabolites of vitamin D3 in the chick | |
| Wu et al. | Regulation of renal vitamin D-24-hydroxylase by phosphate: effects of hypophysectomy, growth hormone and insulin-like growth factor I | |
| US4511564A (en) | Methods of controlling the concentration of calcium in the serum of warm-blooded animals and pharmaceutical compositions to be used therefor | |
| Gray et al. | Effect of age on plasma 1, 25-(OH) 2 vitamin D in the rat | |
| JPH0780773B2 (ja) | 新規ビタミンｄ▲下３▼誘導体を有効成分とする医薬 | |
| Wang et al. | Synthesis of 1α, 25-dihydroxyvitamin D3 analogues with α, α-difluorocycloketone at the CD-ring side chains and their biological properties in ovariectomized rats | |
| Jongen et al. | Effect of dietary calcium, phosphate and vitamin D deprivation on the pharmacokinetics of 1, 25-dihydroxyvitamin D3 in the rat | |
| Napoli et al. | 25, 26-dihydroxyvitamin D3 is not a major intermediate in 25-hydroxyvitamin D3-26, 23-lactone formation | |
| Procsal et al. | Studies on the mode of action of calciferol: Biological activity of 1α, 24R, 25-trihydroxyvitamin D3 in the chick | |
| Nakatsuka et al. | Biological potency of a fluorinated vitamin D analogue in hypoparathyroidism |